View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species
|Evobrutinib exhibits high selectivity for BTK over the EGFR and other Tec family kinases. This profile suggests that evobrutinib is likely to have a reduced potential for off-target related adverse effects compared to existing less selective BTK inhibitors like ibrutinib. The improved selectivity profile and reduced propensity to cause adverse side-effects means that evobrutinib is suitable for evaluation in non-oncology indications. In contrast, the serious side-effects profile of ibrutinib precludes its evaluation in diseases other than life-threatening cancers.